Collaborations & Alliances

AbbVie, Boehringer in Immunology Alliance

To develop and commercialize BI 655066 for immune diseases

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie and Boehringer Ingelheim have entered a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal antibody in Phase III development for psoriasis. The companies are also evaluating the drug’s potential in Crohn’s disease, psoriatic arthritis and asthma. In addition to the anti-IL-23 antibody, AbbVie gains rights to an anti-CD-40 antibody, BI 655064, currently in Phase I development. Boehringer will retain responsibility for further development of BI 65506...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters